Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Ab103
2. Ab103 Peptide
3. P2ta Peptide
4. Spmlvayd
1. 1447799-33-8
2. Reltecimod [inn]
3. Reltecimod [usan]
4. Ab103
5. U00j02uy29
6. (5s,8s,11s,14s,17s,20s,23r)-5-((s)-1-((s)-2-((r)-2-aminopropanamido)-3-hydroxypropanoyl)pyrrolidine-2-carboxamido)-20-(carboxymethyl)-17-(4-hydroxybenzyl)-8-isobutyl-11-isopropyl-14,23-dimethyl-6,9,12,15,18,21-hexaoxo-2-thia-7,10,13,16,19,22-hexaazatetracosan-24-oic Acid
7. Reltecimod (usan/inn)
8. Reltecimod [usan:inn]
9. Unii-u00j02uy29
10. Chembl3989950
11. Hy-p1698
12. Cs-0090321
13. D11281
14. Q27290502
15. D-alanyl(human T-cell-specific Surface Glycoprotein Cd28-(8-15)-peptidyl)-d-alanine
16. D-alanine, D-alanyl-l-seryl-l-prolyl-l-methionyl-l-leucyl-l-valyl-l-alanyl-l-tyrosyl-l-.alpha.-aspartyl-
17. D-alanine, D-alanyl-l-seryl-l-prolyl-l-methionyl-l-leucyl-l-valyl-l-alanyl-l-tyrosyl-l-alpha-aspartyl-
18. D-alanyl-(t-cell-specific Surface Glycoprotein Cd28-(8-15)- Peptide)-d-alanine:d-alanyl-l-seryl-l-prolyl-l-methionyl-l-leucyl-l-valyl-l-alanyl-l-tyrosyl-l-.alpha.-aspartyl-d-alanine Immunomodulator
19. D-alanyl-(t-cell-specific Surface Glycoprotein Cd28-(8-15)- Peptide)-d-alanine:d-alanyl-l-seryl-l-prolyl-l-methionyl-l-leucyl-l-valyl-l-alanyl-l-tyrosyl-l-alpha-aspartyl-d-alanine Immunomodulator
20. D-alanyl-l-seryl-l-prolyl-l-methionyl-l-leucyl-l-valyl-l-alanyl-l-tyrosyl-l-aspartyl-d-alanine
| Molecular Weight | 1037.2 g/mol |
|---|---|
| Molecular Formula | C46H72N10O15S |
| XLogP3 | -2.7 |
| Hydrogen Bond Donor Count | 13 |
| Hydrogen Bond Acceptor Count | 17 |
| Rotatable Bond Count | 29 |
| Exact Mass | 1036.48993280 g/mol |
| Monoisotopic Mass | 1036.48993280 g/mol |
| Topological Polar Surface Area | 420 Ų |
| Heavy Atom Count | 72 |
| Formal Charge | 0 |
| Complexity | 1920 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 10 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
78
PharmaCompass offers a list of Reltecimod API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Reltecimod manufacturer or Reltecimod supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Reltecimod manufacturer or Reltecimod supplier.
PharmaCompass also assists you with knowing the Reltecimod API Price utilized in the formulation of products. Reltecimod API Price is not always fixed or binding as the Reltecimod Price is obtained through a variety of data sources. The Reltecimod Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Reltecimod manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Reltecimod, including repackagers and relabelers. The FDA regulates Reltecimod manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Reltecimod API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Reltecimod supplier is an individual or a company that provides Reltecimod active pharmaceutical ingredient (API) or Reltecimod finished formulations upon request. The Reltecimod suppliers may include Reltecimod API manufacturers, exporters, distributors and traders.
Reltecimod Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Reltecimod GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Reltecimod GMP manufacturer or Reltecimod GMP API supplier for your needs.
A Reltecimod CoA (Certificate of Analysis) is a formal document that attests to Reltecimod's compliance with Reltecimod specifications and serves as a tool for batch-level quality control.
Reltecimod CoA mostly includes findings from lab analyses of a specific batch. For each Reltecimod CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Reltecimod may be tested according to a variety of international standards, such as European Pharmacopoeia (Reltecimod EP), Reltecimod JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Reltecimod USP).
